Citations

Clear

9383 citation(s) found for "Thomas, PS".

Prostate Cancer, Version 3.2024
Schaeffer, Edward M. , Srinivas, Sandy, An, Yi , Bitting, Rhonda L. , Chapin, Brian F. , D’Amico, Anthony V. , Desai, Neil , Dorff, Tanya B. , Eastham, James A., Farrington, Thomas A., Gupta, Shilpa , Guzzo, Thomas, Karnes, R. Jeffrey , Kuettel, Michael, McKay, Rana R. , Morgan, Todd M. , Pow‐Sang, Julio M. , Reiter, Robert E. , Roach, Mack , Rosenfeld, Stan, Shabsigh, Ahmad , Valicenti, Richard K., Wong, J.K. , Snedeker, Jenna, Freedman-Cass, Deborah A., Morgan, Todd M , Robin, Tyler P. , Adra, Nabil , Cheng, Heather H. , Gao, Xin Yuan , Ippolito, Joseph E. , Lang, Joshua M. , Lotan, Tamara Levin , Spratt, Daniel E. , Szmulewitz, Russell Z , Teply, Benjamin A. , Tward, Jonathan D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 16, 2024 | Volume: 22 | Issue: 3 | Pages: 140-150

10.6004/jnccn.2024.0019 | PMID 38626801 Get It

The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions for the 2024 update to the guidelines with regard to initial risk stratification, initial management of very-low-risk disease, and the treatment of nonmetastatic recurrence.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
Wierda, William G. , Brown, Jennifer R. , Bilgrami, S, Bociek, Greg, Brander, Danielle M. , Cortese, Matthew J , Cripe, Larry D., Davis, Randall S. , Eradat, Herbert, Fakhri, Bita , Fletcher, Christopher D.�M. , Gaballa, Sameh , Hamid, Muhammad Saad , Hill, Brian T. , Kaesberg, Paul, Kamdar, Manali , Ma, Shuo , Mosse, Claudio A. , Nakhoda, Shazia , Schorr, Andrew, Seshadri, Madhav , Stephens, Deborah M. , Ujjani, Chaitra S. , Valdez, Riccardo, Wagner‐Johnston, Nina D. , Woyach, Jennifer A. , Sundar, Hema, Dwyer, Mary A., Stephens, Deborah M , Kamdar, Manali , Ma, Shuo , Fakhri, Bita , Wierda, William G. , Abramson, Jeremy S. , Awan, Farrukh T. , Kahl, Brad S. , Kipps, Thomas J. , Parikh, Sameer A. , Schuster, Stephen J. , Siddiqi, Tanya , Thompson, Meghan C

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 16, 2024 | Volume: 22 | Issue: 3 | Pages: 175-204

10.6004/jnccn.2024.0018 | PMID 38626800 Get It

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based on the disease stage, presence or absence of del(17p) or TP53 mutation, immunoglobulin heavy chain variable region mutation status, patient age, performance status, comorbid conditions, and the agent’s toxicity profile. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.
Ischiorectal Fossa Tumors: 30-year Single-Institution Experience
Peponis, Thomas , Perry, William , Perry, William , Perry, William R , Kelley, Scott R.

Mayo Clinic

Diseases of the Colon & Rectum | April 16, 2024 | Volume: 67 | Issue: 7 | Pages: 896-902

10.1097/dcr.0000000000003255 | PMID 38624099 Get It

BACKGROUND: Primary tumors of the ischiorectal fossa are rare and comprise a wide array of pathologies with varying malignant potential. Because of the low prevalence, there is a paucity of data in the literature. This article presents a case series on the management of ischiorectal fossa tumors. OBJECTIVE: To present experience from 30 years of managing ischiorectal fossa tumors. DESIGN: Retrospective single-center analysis. SETTINGS: A quaternary referral academic health care center. PATIENTS: All patients treated for ischiorectal fossa tumors were included in the study. INTERVENTIONS: All patients underwent surgical management of their disease. MAIN OUTCOME MEASURES: Disease recurrence and overall survival. RESULTS: A total of 34 patients (53% women) were identified with a median follow-up of 23 months. Twenty-one patients (62%) were diagnosed with benign and 13 (38%) with malignant tumors. All underwent surgical resection. The median tumor size was 8.4 cm. R0 resection was obtained in 28 patients. Twelve patients (35%) developed recurrence (9 after R0 resection) after a median time of 6.5 months. There were no surgical-related mortalities. LIMITATIONS: Limitations to the study include its retrospective nature, single-center experience, and small patient sample size. CONCLUSIONS: Ischiorectal fossa tumors are primarily benign; however, they are associated with high recurrence rates even in the setting of an R0 resection. Treatment should be approached in a multidisciplinary manner, preferably in centers with experience treating these tumors. Close posttreatment surveillance is imperative. See Video Abstract. TUMORES DE LA FOSA ISQUIORRECTAL: EXPERIENCIA DE 30 AÑOS EN UNA SOLA INSTITUCIÓN ANTECEDENTES: Los tumores primarios de la fosa isquiorrectal son raros y comprenden una amplia gama de patologías con potencial maligno variable. Debido a la baja prevalencia, hay escasez de datos en la literatura. Este artículo presenta una serie de casos sobre el tratamiento de los tumores de la fosa isquiorrectal. OBJETIVO: Presentar una experiencia de 30 años en el manejo de tumores de la fosa isquiorrectal. DISEÑO: Análisis retrospectivo de un solo centro. AJUSTES: Un centro de atención médica académico de referencia cuaternaria. PACIENTES: Todos los pacientes tratados por tumores de la fosa isquiorrectal. INTERVENCIONES: Todos los pacientes se sometieron a tratamiento quirúrgico de su enfermedad. PRINCIPALES MEDIDAS DE RESULTADO: Recurrencia de la enfermedad y supervivencia general. RESULTADOS: Se identificaron un total de 34 pacientes (53% mujeres) con una mediana de seguimiento de 23 meses. Veintiún pacientes (62%) fueron diagnosticados con tumores benignos y 13 (38%) con tumores malignos. Todos fueron sometidos a resección quirúrgica. El tamaño medio del tumor fue de 8,4 cm. La resección R0 se obtuvo en 28 pacientes. Doce (35%) desarrollaron recurrencia (nueve después de la resección R0) con una mediana de tiempo de 6,5 meses. No hubo mortalidades relacionadas con la cirugía. LIMITACIONES: Las limitaciones del estudio incluyen su naturaleza retrospectiva, experiencia en un solo centro y tamaño pequeño de la muestra de pacientes. CONCLUSIONES: Los tumores de la fosa isquiorrectal son principalmente benignos, sin embargo, se asocian con altas tasas de recurrencia incluso en el contexto de una resección R0. El tratamiento debe abordarse de forma multidisciplinaria y preferentemente en centros con experiencia en el tratamiento de estos tumores. Vigilancia cercana posterior al tratamiento es imperativa. (Traducción—Dr. Aurian Garcia Gonzalez)
Decoding Immuno-Competence: A Novel Analysis of Complete Blood Cell Count Data in COVID-19 Outcomes
Kempaiah, Prakasha , Libertin, Claudia R. , Chitale, Rohit , Naeyma, Islam, Pleqi, Vasili, Sheele, Johnathan M. , Iandiorio, Michelle, Hoogesteijn, Almira L. , Caulfield, Thomas R. , Rivas, Ariel L. , Chitale, Rohit A, Caulfield, Thomas R , Libertin, Claudia , Kempaiah, Prakasha , Sheele, Johnathan M

Mayo Clinic

Biomedicines | April 16, 2024 | Volume: 12 | Issue: 4 | Pages: 871

10.3390/biomedicines12040871 | PMID 38672225 Get It

Background: While ‘immuno-competence’ is a well-known term, it lacks an operational definition. To address this omission, this study explored whether the temporal and structured data of the complete blood cell count (CBC) can rapidly estimate immuno-competence. To this end, one or more ratios that included data on all monocytes, lymphocytes and neutrophils were investigated. Materials and methods: Longitudinal CBC data collected from 101 COVID-19 patients (291 observations) were analyzed. Dynamics were estimated with several approaches, which included non-structured (the classic CBC format) and structured data. Structured data were assessed as complex ratios that capture multicellular interactions among leukocytes. In comparing survivors with non-survivors, the hypothesis that immuno-competence may exhibit feedback-like (oscillatory or cyclic) responses was tested. Results: While non-structured data did not distinguish survivors from non-survivors, structured data revealed immunological and statistical differences between outcomes: while survivors exhibited oscillatory data patterns, non-survivors did not. In survivors, many variables (including IL-6, hemoglobin and several complex indicators) showed values above or below the levels observed on day 1 of the hospitalization period, displaying L-shaped data distributions (positive kurtosis). In contrast, non-survivors did not exhibit kurtosis. Three immunologically defined data subsets included only survivors. Because information was based on visual patterns generated in real time, this method can, potentially, provide information rapidly. Discussion: The hypothesis that immuno-competence expresses feedback-like loops when immunological data are structured was not rejected. This function seemed to be impaired in immuno-suppressed individuals. While this method rapidly informs, it is only a guide that, to be confirmed, requires additional tests. Despite this limitation, the fact that three protective (survival-associated) immunological data subsets were observed since day 1 supports many clinical decisions, including the early and personalized prognosis and identification of targets that immunomodulatory therapies could pursue. Because it extracts more information from the same data, structured data may replace the century-old format of the CBC.
Numbers of prenatal cell‐free DNA screens performed: Results of a 2022 CAP exercise
Richards, C. Sue , Wyatt, Philip, Rowsey, Ross, Cacheris, Phillip Michael , Lepage, Nathalie , Natowicz, Marvin R. , Long, Thomas , Moyer, Ann M. , Richards, C. Sue

Mayo Clinic

Prenatal Diagnosis | April 16, 2024 | Volume: 44 | Issue: 8 | Pages: 946-952

10.1002/pd.6574 | PMID 38622635 Get It

AbstractObjectiveDetermine current analytical methods and number of cell‐free (cf) DNA prenatal screening tests performed for common trisomies.MethodsThe College of American Pathologists 2022‐B Noninvasive Prenatal Testing exercise was distributed in December 2022 to 93 participants in 22 countries. Supplemental questions included the number of tests performed in a recent month and the proportion of samples originating outside the United States (US).ResultsEighty‐three participants from three continents returned results; 74 (89%) were suitable for the analyses. Nine manufacturer/platform combinations were identified, most commonly Illumina/Nextseq (55%). The most common methodology was whole genome sequencing (76%). Annualized cfDNA tests were 2.80 million, with Asian, European and North American participants representing 10.6%, 6.5% and 82.9% of tests, respectively. When restricted to US in‐country tests, the annualized rate was 2.18 million, with four of 20 participants testing 79.2%. Among 73 respondents, 63 (86%) were for‐profit, eight (11%) were non‐profit academic or government supported and the remaining two included hospital‐based and private non‐profit. Eighteen (25%) supported relevant academic training.ConclusionIn 2011, screening for common trisomies was based on serum/ultrasound markers with an estimated 2.96 million US pregnancies screened in 131 laboratories. In 2022, cfDNA‐based screening was offered by 20 laboratories testing 2.18 million US pregnancies.
Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma
Klatte, Derk C.F. , Starr, Jason S. , Clift, Kristin , Hardway, Heather D , Hooft, Jeanin E. van , Leerdam, Monique E. van , Potjer, Thomas P. , Presutti, R. John , Riegert‐Johnson, Douglas L. , Wallace, Michael B. , Bi, Yan , Clift, Kristin E , van Hooft, Jeanin E , van Leerdam, Monique E , Presutti, Richard J , Wallace, Michael B , Klatte, D C F , Hardway, Heather

Mayo Clinic

JCO Oncology Practice | April 15, 2024 | Volume: 20 | Issue: 8 | Pages: 1081-1090

10.1200/op.23.00447 | PMID 38621197 Get It

PURPOSE Guidelines recommend germline genetic testing (GT) for patients with pancreatic ductal adenocarcinoma (PDAC). This study aims to evaluate the utilization and outcomes of multigene panel GT in patients with PDAC. METHODS This retrospective, multisite study included patients with PDAC diagnosed between May 2018 and August 2020 at Mayo Clinic Arizona, Florida, and Minnesota. Discussion, uptake, and outcomes of GT were compared before (May 1, 2018-May 1, 2019) and after (August 1, 2019-August 1, 2020) the guideline update, accounting for a transition period. RESULTS The study identified 533 patients with PDAC, with 321 (60.2%) preguideline and 212 (39.8%) postguideline. Patient characteristics did not differ between the preguideline and postguideline periods. GT was discussed in 34.3% (110 of 321) of preguideline and 39.6% (84 of 212) of postguideline patients (odds ratio [OR], 1.26 [95% CI, 0.88 to 1.80]) and subsequently performed in 80.9% (89 of 110) of preguideline and 75.0% (63 of 84) of postguideline patients (OR, 1.10 [95% CI, 0.75 to 1.61]). Of 152 tested patients, 26 (17.1%) had a pathogenic variant (PV), of whom 17 (11.2%; 17 of 152) were PDAC-associated. Over the entire study period, GT was more likely in younger patients (65 v 70 years; P < .001), those seen by a medical oncologist (82.9% v 69.0%; P < .001), and those surviving more than 12 months from diagnosis (70.4% v 43.4%; P < .001). Demographics and personal/family cancer history were comparable between patients with and without a PDAC PV. CONCLUSION GT remains underutilized despite National Comprehensive Cancer Network guideline recommendations. Given the poor prognosis of PDAC and potential implications of GT, efforts to increase utilization are needed to provide surveillance and support to both patients with PDAC and at-risk family members.
Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2
Bryce, Alan H. , Crawford, E. David , Beltran, Himisha , Petrylak, Daniel P. , Armstrong, Andrew J. , Boike, Thomas , Calais, Jérémie , Chapin, Brian F. , Cookson, Michael S. , Davis, John W. , Dorff, Tanya B. , Eggener, Scott E. , Feng, Felix Y. , Higano, Celestia S. , Poage, Wendy, Scher, Howard I. , Sieber, Paul , Srinivas, Sandy, Zhang, Tian , Koo, Phillip J. , Beltran, Himisha , Cooperberg, Matthew R , Antonarakis, Emmanuel S , Aparicio, Ana M , Calais, Jeremie , Morris, Michael J , Scher, Howard I , Bryce, Alan H , Armstrong, Andrew J , Agarwal, Neeraj , Hussain, Maha , Shore, Neal D. , Spratt, Daniel E. , Tagawa, Scott T. , Carducci, Michael A. , Gleave, Martin , Iagaru, Andrei H. , Morgans, Alicia K. , Morris, Michael J. , Murray, Katie S. , Rettig, Matthew B. , Sartor, Oliver , Small, Eric J. , Yu, Evan Y

Mayo Clinic

JU Open Plus | April 15, 2024 | Volume: 2 | Issue: 4 | Pages: No page available

10.1097/ju9.0000000000000138 | PMID 38774467 Get It

Background: Management strategies for metastatic castration-resistant prostate cancer (mCRPC) have rapidly shifted in recent years. As novel imaging and therapeutic approaches have made their way to the clinic, providers are encountering increasingly challenging clinical scenarios, with limited guidance from the current literature. Materials and Methods: The US Prostate Cancer Conference (USPCC) is a multidisciplinary meeting of prostate cancer experts intended to address the many challenges of prostate cancer management. At the first annual USPCC meeting, areas of controversy and consensus were identified during a 2-day meeting that included expert presentations, full-panel discussions, and postdiscussion responses to questions developed by the USPCC cochairs and session moderators. Results: This narrative review covers the USPCC expert discussion and perspectives relevant to mCRPC, including neuroendocrine/aggressive-variant prostate cancer (NEPC/AVPC). Areas of broad agreement identified among USPCC experts include the benefits of poly (ADP-ribose) polymerase (PARP) inhibitors for patients with BRCA1/2 mutations, the use of radioligand therapy in patients with prostate-specific membrane antigen (PSMA)–positive mCRPC, and the need for clinical trials that address real-world clinical questions, including the performance of novel therapies when compared with modern standard-of-care treatment. Ongoing areas of controversy and uncertainty included the appropriateness of PARP inhibitors in patients with non-BRCA1/2 mutations, the optimal definition of PSMA positivity, and systemic therapies for patients with NEPC/AVPC after progression on platinum-based therapies. Conclusions: The first annual USPCC meeting identified several areas of controversy in the management of mCRPC, highlighting the urgent need for clinical trials designed to facilitate treatment selection and sequencing in this heterogeneous disease state.
Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1
Crawford, E. David , Beltran, Himisha , Petrylak, Daniel P. , Armstrong, Andrew J. , Boike, Thomas , Calais, Jérémie , Chapin, Brian F. , Cookson, Michael S. , Davis, John W. , Dorff, Tanya B. , Eggener, Scott E. , Feng, Felix Y. , Higano, Celestia S. , Poage, Wendy, Scher, Howard I. , Sieber, Paul , Srinivas, Sandy, Zhang, Tian , Koo, Phillip J. , Antonarakis, Emmanuel S , Aparicio, Ana M , Calais, Jeremie , Scher, Howard I , Armstrong, Andrew J , Bryce, Alan H. , Hussain, Maha , Agarwal, Neeraj , Cooperberg, Matthew R , Shore, Neal D. , Spratt, Daniel E. , Tagawa, Scott T. , Carducci, Michael A. , Gleave, Martin , Iagaru, Andrei H. , Morgans, Alicia K. , Morris, Michael J. , Murray, Katie S. , Rettig, Matthew B. , Sartor, Oliver , Small, Eric J. , Yu, Evan Y

Mayo Clinic

JU Open Plus | April 15, 2024 | Volume: 2 | Issue: 4 | Pages: No page available

10.1097/ju9.0000000000000137 | PMID 38774466 Get It

Purpose: Castration-sensitive prostate cancer (CSPC) is a complex and heterogeneous condition encompassing a range of clinical presentations. As new approaches have expanded management options, clinicians are left with myriad questions and controversies regarding the optimal individualized management of CSPC. Materials and Methods: The US Prostate Cancer Conference (USPCC) multidisciplinary panel was assembled to address the challenges of prostate cancer management. The first annual USPCC meeting included experts in urology, medical oncology, radiation oncology, and nuclear medicine. USPCC co-chairs and session moderators identified key areas of controversy and uncertainty in prostate cancer management and organized the sessions with multidisciplinary presentations and discussion. Throughout the meeting, experts responded to questions prepared by chairs and moderators to identify areas of agreement and controversy. Results: The USPCC panel discussion and question responses for CSPC-related topics are presented. Key advances in CSPC management endorsed by USPCC experts included the development and clinical utilization of gene expression classifiers and artificial intelligence (AI) models for risk stratification and treatment selection in specific patient populations, the use of advanced imaging modalities in patients with clinically localized unfavorable intermediate or high-risk disease and those with biochemical recurrence, recommendations of doublet or triplet therapy for metastatic CSPC (mCSPC), and consideration of prostate and/or metastasis-directed radiation therapy in select patients with mCSPC. Conclusions: CSPC is a diverse disease with many therapeutic options and the potential for adverse outcomes associated with either undertreatment or overtreatment. Future studies are needed to validate and clinically integrate novel technologies, including genomics, AI, and advanced imaging, to optimize outcomes among patients with CSPC.
Postoperative C5 Palsy after Anterior or Posterior Decompression for Degenerative Cervical Myelopathy
Bak, Alex B. , Moghaddamjou, Ali, Ahn, Henry, Shaffrey, Christopher I. , Mummaneni, Praveen V. , Jacobs, W. Bradley , Riew, K. Daniel , Hilibrand, Alan S. , Kim, Kee D. , Fourney, Daryl R. , Santaguida, Carlo , Massicotte, Eric M. , Kopjar, Branko , Alvi, Mohammed Ali , Farhadi, H. Francis , Nassr, Ahmad , Arnold, Paul M. , Riew, Kiehyun Daniel , Kelly, Michael P. , Brodke, Darrel Scott , Vaccaro, Alexander R. , Wilson, Jason, Harrop, James Shields , Fehlings, Michael G.

Mayo Clinic

Spine | April 15, 2024 | Volume: 49 | Issue: 20 | Pages: 1410-1416

10.1097/brs.0000000000005007 | PMID 38616732 Get It

Study Design. Retrospective cohort study of prospectively accrued data. Objective. To evaluate a large, prospective, multicentre dataset of surgically treated degenerative cervical myelopathy (DCM) cases on the contemporary risk of C5 palsy with surgical approach. Summary of Background Data. The influence of surgical technique on postoperative C5 palsy after decompression for DCM is intensely debated. Comprehensive, covariate-adjusted analyses are needed using contemporary data. Methods. Patients with moderate to severe DCM were prospectively enrolled in the multicenter, randomized, Phase III CSM-Protect clinical trial and underwent either anterior or posterior decompression between Jan 31, 2012 and May 16, 2017. The primary outcome was the incidence of postoperative C5 palsy, defined as the onset of muscle weakness by at least one grade in manual muscle test at the C5 myotome with slight or absent sensory disruption after cervical surgery. Two comparative cohorts were made based on the anterior or posterior surgical approach. Multivariate hierarchical mixed-effects logistic regression was used to estimate odds ratios (OR) with 95% confidence intervals (CI) for C5 palsy. Results. A total of 283 patients were included, and 53.4% underwent posterior decompression. The total incidence of postoperative C5 palsy was 7.4% and was significantly higher in patients who underwent posterior decompression compared with anterior decompression (11.26% vs. 3.03%, P=0.008). After multivariable regression, the posterior approach was independently associated with greater than four times the likelihood of postoperative C5 palsy (P=0.017). Rates of C5 palsy recovery were comparable between the two surgical approaches. Conclusion. The odds of postoperative C5 palsy are significantly higher after posterior decompression compared to anterior decompression for DCM. This may influence surgical decision-making when there is equipoise in deciding between anterior and posterior treatment options for DCM. Level of Evidence. Therapeutic Level—II